NU6027: A New Drug for Breast and Ovarian Cancer
Author Information
Author(s): Peasland A, Wang L-Z, Rowling E, Kyle S, Chen T, Hopkins A, Cliby W A, Sarkaria J, Beale G, Edmondson R J, Curtin N J
Primary Institution: Newcastle University, Northern Institute for Cancer Research
Hypothesis
NU6027 may inhibit ATR and enhance the effectiveness of DNA-damaging chemotherapy agents.
Conclusion
NU6027 inhibits ATR, impairing G2/M arrest and homologous recombination, thus increasing sensitivity to DNA-damaging agents and PARP inhibitors.
Supporting Evidence
- NU6027 is a potent inhibitor of ATR activity with an IC50 of 6.7 μM.
- NU6027 enhances the cytotoxicity of cisplatin and hydroxyurea in cancer cells.
- NU6027 was synthetically lethal when combined with PARP inhibitors in cells with DNA repair defects.
Takeaway
NU6027 is a new drug that helps cancer treatments work better by stopping cancer cells from repairing their DNA.
Methodology
The study involved testing NU6027's effects on ATR activity, cell cycle effects, and chemosensitization in various cancer cell lines.
Limitations
The study does not address in vivo effects or long-term safety of NU6027.
Statistical Information
P-Value
p=0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website